[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
3. Hussein HA, Goda HA: Paravertebral neurogenic tumors with intraspinal extension: preoperative evaluation and surgical approach. J Egypt Natl Canc Inst; 2009 Mar;21(1):12-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign schwannoma were diagnosed in 5 cases, malignant schwannoma in 3, neurofibromatosis in one case, neuroblastoma in 3 cases, ganglioneuroblastoma in 2 cases and ganglioneuroma in 2 cases.
  • C-T guided biopsy can select patients with pathological diagnosis that could be sensitive to pre operative chemotherapy and/or radiotherapy to facilitate surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601967.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. Johnson TE, Toledano SR: Ganglioneuroblastoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2003 Jul;19(4):330-3
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioneuroblastoma metastatic to the orbit.
  • A 10-month-old girl presented with an extensive orbital and cranial metastatic lesion from an adrenal ganglioneuroblastoma.
  • Treatment with chemotherapy alone resulted in complete regression of the tumors with over 7 years of follow-up.
  • Good prognostic indicators included her young age at diagnosis, DNA index of tumor cells of 1.4, and the histologic subtype of neuroblastic tumor.
  • This is the first reported case of ganglioneuroblastoma metastatic to the orbit.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Ganglioneuroblastoma / secondary. Orbital Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Humans. Infant. Nerve Tissue Proteins / analysis. Skull Neoplasms / diagnosis. Skull Neoplasms / drug therapy. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12878887.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins
  •  go-up   go-down


5. Ito A, Uno T, Gunji Y, Yamauchi T, Egami S, Kawarasaki H, Momoi MY: Obstructive jaundice as a presentation of ganglioneuroblastoma. J Pediatr Hematol Oncol; 2005 Feb;27(2):112-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice as a presentation of ganglioneuroblastoma.
  • Seven cases of obstructive jaundice caused by neuroblastoma have been reported, and only three of these patients had the symptom at the onset of the disease.
  • The authors report a case of ganglioneuroblastoma presenting with obstructive jaundice as a rare initial feature.
  • After the histologic diagnosis with open biopsy, chemotherapy consisting of cisplatin, pirarubicin hydrochloride/doxorubicin, cyclophosphamide, and vincristine was given.
  • The treatment resulted in reduction in the tumor size and relief of the obstructive jaundice.
  • Complete resection of the tumor was possible after five courses of chemotherapy.
  • [MeSH-major] Doxorubicin / analogs & derivatives. Ganglioneuroblastoma / complications. Jaundice, Obstructive / etiology. Retroperitoneal Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Humans. Male. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701990.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL: Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics; 2002 Jul-Aug;22(4):911-34
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation.
  • Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma are tumors of the sympathetic nervous system that arise from primitive sympathogonia and are referred to collectively as neuroblastic tumors.
  • They arise wherever sympathetic tissue exists and may be seen in the neck, posterior mediastinum, adrenal gland, retroperitoneum, and pelvis.
  • Ganglioneuroblastoma is composed of both mature gangliocytes and immature neuroblasts and has intermediate malignant potential.
  • Neuroblastoma is the most immature, undifferentiated, and malignant tumor of the three.
  • Treatment consists of surgery and, usually, chemotherapy.
  • Despite recent advances in treatment, including bone marrow transplantation, neuroblastoma remains a relatively lethal tumor, accounting for 10% of pediatric cancers but 15% of cancer deaths in children.
  • [MeSH-minor] Ganglioneuroblastoma / pathology. Ganglioneuroblastoma / radiography. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Prognosis. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2002
  • (PMID = 12110723.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


7. Santos A, Calvet L, Terrier-Lacombe MJ, Larsen A, Bénard J, Pondarré C, Aubert G, Morizet J, Lavelle F, Vassal G: In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. Cancer Res; 2004 May 1;64(9):3223-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
  • Topoisomerase I inhibitors, such as CPT-11, are potent anticancer drugs against neuroblastoma (NB).
  • Prolonged stable disease was observed, resulting in an overall tumor growth delay of 115 days.
  • During treatment, tumors differentiated into ganglioneuroblastomas (GGNB), which reverted into an immature phenotype when treatment was discontinued.
  • The full-length Mr 100,000 topo I protein was present in both pre and post-treatment immature NB xenografts.
  • [MeSH-major] Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Enzyme Inhibitors / pharmacology. Neuroblastoma / drug therapy. Neuroblastoma / enzymology. Topoisomerase I Inhibitors
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Cell Differentiation / drug effects. Cell Division / drug effects. Child. Child, Preschool. DNA Topoisomerases, Type I / metabolism. Female. Humans. Infant. Infant, Newborn. Male. Mice. Mice, Nude. Retinaldehyde / pharmacology. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15126363.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 472-86-6 / 13-cis-retinal; 7673326042 / irinotecan; EC 5.99.1.2 / DNA Topoisomerases, Type I; RR725D715M / Retinaldehyde; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


8. Stefanowicz J, Izycka-Swieszewska E, Drozyńska E, Pienczk J, Połczyńska K, Czauderna P, Sierota D, Bień E, Stachowicz-Stencel T, Kosiak W, Balcerska A: Neuroblastoma and opsoclonus-myoclonus-ataxia syndrome--clinical and pathological characteristics. Folia Neuropathol; 2008;46(3):176-85
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two of the children the onset of neurological symptoms was connected with a vaccination and in one with viral infection.
  • All cases were in stage II or III of the disease, with no metastases or MYCN amplification.
  • The group included two ganglioneuroblastomas, one ganglioneuroma and one differentiating neuroblastoma.
  • Immunohistochemical analysis of inflammatory infiltrations revealed mixed type populations of lymphocytes with prevalence of the cytotoxic type (CD8 and CD56-positive cells).
  • All patients were treated by surgery alone or with adjuvant chemotherapy with a positive outcome.


9. Zangeneh F, Young WF Jr, Lloyd RV, Chiang M, Kurczynski E, Zangeneh F: Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma. Endocr Pract; 2003 Sep-Oct;9(5):394-9
MedlinePlus Health Information. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma.
  • OBJECTIVE: To report the first recognized case of Cushing's syndrome due to a corticotropin-releasing hormone (CRH)-secreting ganglioneuroblastoma, which was found in an 18-month-old boy with hypertensive encephalopathy.
  • RESULTS: An 18-month-old boy with a history of recent weight gain was admitted because of sudden onset of right fixed esotropia and left facial palsy after episodes of emesis.
  • Despite discordant dynamic endocrine testing and negative somatostatin receptor scintigraphy, computed tomography showed a right 3.6- by 3.0-cm extra-adrenal retroperitoneal mass with central calcification extending 7 cm cephalocaudally.
  • The patient underwent exploratory laparotomy, followed by chemotherapy.
  • Findings on light microscopic and immunohistochemical examination of the retroperitoneal mass were consistent with a ganglioneuroblastoma that expressed CRH, pro-opiomelanocortin, and ACTH.
  • In this case, it was due to ectopic production of CRH by a ganglioneuroblastoma.
  • [MeSH-major] Corticotropin-Releasing Hormone / metabolism. Cushing Syndrome / etiology. Ganglioneuroblastoma / complications. Retroperitoneal Neoplasms / complications
  • [MeSH-minor] Humans. Immunohistochemistry. Infant. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14583423.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


10. Spugnini EP, Citro G, Dotsinsky I, Mudrov N, Mellone P, Baldi A: Ganglioneuroblastoma in a cat: a rare neoplasm treated with electrochemotherapy. Vet J; 2008 Nov;178(2):291-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioneuroblastoma in a cat: a rare neoplasm treated with electrochemotherapy.
  • A diagnosis of ganglioneuroblastoma was suggested by the tumour appearance following histopathological staining with haematoxylin and eosin and haematoxylin/van Gieson.
  • Immunohistochemical staining for glial fibrillary acidic protein (GFAP), vimentin, neuron-specific enolase (NSE), neurofilament and S100 further confirmed the diagnosis.
  • The tumour had completely regressed within 1 week of the third ECT application and remained in remission for 402 days at which time a small recurrence was noted.
  • Electrochemotherapy is considered a safe and effective treatment for localised neoplasms of cats and dogs and warrants further investigation.
  • [MeSH-major] Cat Diseases / drug therapy. Electrochemotherapy / veterinary. Ganglioneuroblastoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cats. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910926.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


11. Mizuno S, Iida T, Fujita S: Adult-onset adrenal ganglioneuroblastoma - Bone metastasis two years after surgery: report of a case. Surg Today; 2010 May;40(5):482-6
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-onset adrenal ganglioneuroblastoma - Bone metastasis two years after surgery: report of a case.
  • Ganglioneuroblastoma (GNB) is a common type of tumor in children but is rarely seen in adults.
  • Histologically, on gross examination the tumor contained a visible neuroblastomatous nodule with ganglioneuromatous component, and was diagnosed as GNB nodular classical type.
  • Because the prognosis was not favorable, despite surgery and radiation therapy or chemotherapy, it is necessary to closely follow patients with large GNB tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Ganglioneuroblastoma / pathology. Ganglioneuroblastoma / surgery. Lumbar Vertebrae / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 2004;36(4):481-3 [15787320.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2451-61 [11745303.001]
  • [Cites] Brain Tumor Pathol. 2008;25(1):45-9 [18415666.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2183-96 [1544124.001]
  • [Cites] Br J Radiol. 1997 Jan;70:96-8 [9059304.001]
  • [Cites] Int Abstr Surg. 1954 Oct;99(4):313-41 [13205424.001]
  • [Cites] J Clin Pathol. 1989 Nov;42(11):1148-52 [2584426.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1430-7; discussion 1437-8 [9337686.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:38-46 [17102070.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2197-211 [1544125.001]
  • [Cites] Surg Today. 2007;37(7):612-7 [17593485.001]
  • [Cites] Pediatr Dev Pathol. 2000 Mar-Apr;3(2):184-99 [10679039.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):261-2 [15484706.001]
  • [Cites] Surg Today. 2003;33(10 ):785-90 [14513331.001]
  • [Cites] Eur Radiol. 2002 Dec;12 Suppl 3:S121-6 [12522620.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(6):571-4 [11319584.001]
  • [Cites] South Med J. 2007 Aug;100(8):852-3 [17713319.001]
  • (PMID = 20425556.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Schiavetti A, Ingrosso A, Picone S, Boscherini B: Growth hormone deficiency after localized ganglioneuroblastoma: A case report. J Pediatr Hematol Oncol; 2006 Sep;28(9):625-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone deficiency after localized ganglioneuroblastoma: A case report.
  • Growth hormone deficiency (GHD) related to standard dose chemotherapy has rarely been described.
  • We report on a case of localized ganglioneuroblastoma treated by carboplatin/etoposide for 2 courses and surgery, which developed a serious GHD after 56 months.
  • At present, the child is growing on by GH replacement therapy.
  • We discuss about the hypothesis that GHD may be related to chemotherapy and we report a review of previous published cases.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Ganglioneuroblastoma / drug therapy. Growth Hormone / deficiency
  • [MeSH-minor] Body Height / drug effects. Carboplatin / adverse effects. Etoposide / adverse effects. Humans. Hypothalamus / drug effects. Hypothalamus / pathology. Infant. Male. Pituitary Gland / drug effects. Pituitary Gland / pathology

  • Genetic Alliance. consumer health - Growth Hormone Deficiency.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006271.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 9002-72-6 / Growth Hormone; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Corapcioglu F, Mutlu H, Kara B, Inan N, Akansel G, Gürbüz Y, Topcu S: Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol; 2008 Dec;25(8):756-61
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma.
  • The neurologic symptoms are generally treated with a number of immunosupressive and immunomodulating agents.
  • He had a diagnosis of ganglionueroblastoma at the thoracal paraspinal region.
  • Rituximab therapy was started and continued for total 8 weeks without any side effect.
  • The authors observed excellent neurologic response in the patient at the 4th week of treatment.
  • Rituximab is a new, promising, and safe therapy for OMA syndrome in children with neuroblastoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Ganglioneuroblastoma / drug therapy. Opsoclonus-Myoclonus Syndrome / drug therapy. Prednisolone / therapeutic use


14. Rohrer T, Trachsel D, Engelcke G, Hammer J: Congenital central hypoventilation syndrome associated with Hirschsprung's disease and neuroblastoma: case of multiple neurocristopathies. Pediatr Pulmonol; 2002 Jan;33(1):71-6
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital central hypoventilation syndrome associated with Hirschsprung's disease and neuroblastoma: case of multiple neurocristopathies.
  • We report on a male infant with the rare combined occurrence of congenital central hypoventilation syndrome (CCHS or Ondine's curse), Hirschsprung's disease (HD), and neuroblastoma.
  • We initiated an attempt at curative chemotherapy.
  • We emphasize the importance of screening CCHS patients for associated illnesses such as neuroblastoma and ganglioneuroblastoma at time of diagnosis.
  • [MeSH-major] Abdominal Neoplasms / complications. Hirschsprung Disease / complications. Neuroblastoma / complications. Sleep Apnea, Central / complications


15. Averbuch D, Boekhoutt T, Falk R, Engelhard D, Shapiro M, Block C, Polacheck I: Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii. Med Mycol; 2002 Oct;40(5):479-84
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the recent isolation of Cryptococcus laurentii from the blood of a patient given the diagnosis of ganglioneuroblastoma.
  • Repeated recovery of the organism from different blood cultures, and the patient's good response to treatment with amphotericin B support its etiological role. C. laurentii has rarely been implicated as a cause of clinically significant infections.
  • The identity of reported isolates has not always been adequately documented, and some appear to have been isolated from lesions caused by Cryptococcus neoformans, emphasizing the true rarity of disease due to this fungus.
  • [MeSH-major] Antifungal Agents / pharmacology. Cryptococcus / isolation & purification. Fluconazole / pharmacology. Fungemia / etiology. Ganglioneuroblastoma / complications
  • [MeSH-minor] Adolescent. Cryptococcosis / drug therapy. Cryptococcosis / etiology. Drug Resistance, Fungal. Humans. Male. Microbial Sensitivity Tests. Phylogeny

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12462527.001).
  • [ISSN] 1369-3786
  • [Journal-full-title] Medical mycology
  • [ISO-abbreviation] Med. Mycol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole
  • [Number-of-references] 31
  •  go-up   go-down


16. Moukheiber AK, Nicollas R, Roman S, Coze C, Triglia JM: Primary pediatric neuroblastic tumors of the neck. Int J Pediatr Otorhinolaryngol; 2001 Aug 20;60(2):155-61
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnosis was ganglioneuroblastoma in three cases and neuroblastoma in one case.
  • Cervical computed tomography scan and/or magnetic resonance imaging depicted calcifications within the tumor in 50% of cases and allowed accurate assessment of extension.
  • Surgical treatment was performed in all patients.
  • Neoadjuvant chemotherapy was performed in one case.
  • No evidence of recurrence has been observed with a mean follow-up period of 7 years.
  • [MeSH-major] Ganglioneuroblastoma / diagnosis. Ganglioneuroma / diagnosis. Head and Neck Neoplasms / diagnosis. Neuroblastoma / diagnosis
  • [MeSH-minor] Biopsy, Needle. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Radionuclide Imaging / methods. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11518594.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


17. Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH: Surgical treatment of malignant mediastinal neurogenic tumors in children. Eur J Cardiothorac Surg; 2007 Apr;31(4):725-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of malignant mediastinal neurogenic tumors in children.
  • INTRODUCTION: The aim of this study was to identify the role of surgical resection in the treatment of malignant mediastinal neurogenic tumors in children.
  • MATERIALS AND METHODS: Thirty-eight consecutive children, who underwent surgical resection of a malignant mediastinal neurogenic tumor between 1986 and 2004, were included in this study.
  • The tumor cell types were neuroblastoma in 23 patients (60.5%), ganglioneuroblastoma in 14 (36.8%), and malignant neuroepithelioma in 1 (2.6%).
  • Surgery was performed for curative resection in localized tumors and salvage resection of residual mediastinal masses after chemotherapy in stage IV tumors.
  • Of the 16 patients (42.1%) who underwent salvage resection, 14 had neuroblastoma and 2 ganglioneuroblastoma.
  • CONCLUSIONS: Surgical resection of localized malignant mediastinal neurogenic tumor in children showed good long-term survival, and salvage operations after chemotherapy showed acceptable long-term survival.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Ganglioneuroblastoma / mortality. Ganglioneuroblastoma / surgery. Humans. Infant. Infant, Newborn. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Neuroblastoma / mortality. Neuroblastoma / surgery. Postoperative Complications. Preoperative Care / methods. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306984.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Tang KT, Lee HC, Liang DC, Chen SH, Liu HC, Sheu JC: Neural-crest tumor presenting with chronic diarrhea: a report of three cases. J Formos Med Assoc; 2002 Dec;101(12):864-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients (two girls and one boy aged between 15 to 28 mo) presented with a 3-week to 6-month history of chronic diarrhea of unknown cause.
  • A posterior mediastinal mass or abdominal mass found on sonography and chest roentgenography eventually led to the diagnosis of neural-crest tumor in these patients.
  • Pathology revealed ganglioneuroblastoma in two cases and neuroblastoma in one.
  • All three patients received chemotherapy and underwent surgery.
  • Although one of the patients died of septic shock during chemotherapy, the other two remained free of disease at 30 and 22 months of postoperative follow-up, respectively.


19. Blokker RS, Smit LM, van den Bos C, Overberg PC, Caron HN, Kaspers GJ: [A boy with acute cerebellar ataxia without opsoclonus caused by neuroblastoma]. Ned Tijdschr Geneeskd; 2006 Apr 8;150(14):799-803
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Een jongen met acute cerebellaire ataxie zonder opsoclonus, door een neuroblastoom.
  • Treatment with a curative intent was successful and consisted of metaiodobenzylguanidine I 131, chemotherapy, tumour resection, chemotherapy again and follow-up treatment with isotretinoin after irradiation.
  • The mean time between initial presentation and diagnosis ofneuroblastoma or ganglioneuroblastoma was 12 months.
  • [MeSH-minor] Acute Disease. Child, Preschool. Humans. Male. Ocular Motility Disorders / epidemiology

  • Genetic Alliance. consumer health - Cerebellar Ataxia.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Ataxia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649400.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • The cells of ganglioneuroblastoma-like area were positive for neural markers (Synaptophysin, S-100 protein, neuron-specific enolase).
  • In spite of aggressive combination chemotherapy and three times of laparotomy, the patient died of disease 3 years 10 months after the initial treatment.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


23. Ravindra S, Kini U: Cytomorphology and morphometry of small round-cell tumors in the region of the kidney. Diagn Cytopathol; 2005 Apr;32(4):211-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small round-cell tumors (SRCTs), with malignant cell components measuring 10 m or less in diameter with scanty cytoplasm in alcohol-fixed smears, pose a diagnostic challenge at fine-needle aspiration cytology (FNAC), especially when they are situated in and around the kidney and need facilities such as electron microscopy, immunohistochemistry, tissue culture, and cytogenetics for their subtyping.
  • A precise cytodiagnosis of SRCTs is important because a definite diagnosis is mandatory in preoperative diagnostic workup for presurgical chemotherapy in these cases.
  • With this view in mind, an attempt has been made to diagnose SRCTs in the region of the kidney based on cytomorphology and morphometry alone so as to facilitate its diagnosis in a simple cytology laboratory of a developing country where facilities for auxiliary techniques are not easily available.
  • An aspirate with preponderant malignant round cells that were larger or double the size of red blood cells in air-dried smears or measured less than 10 micro in diameter in alcohol-fixed smears was considered as a small blue-cell tumor.
  • Twenty-one were diagnosed as Wilms' tumor (WT), 10 were diagnosed as neuroblastoma (NB), 3 were ganglioneuroblastoma (GNB), 1 was a cellular congenital mesoblastic nephroma (CMN), and 1 was an adrenocortical carcinoma (ACC).
  • The latter were appreciated only on retrospective analysis after histological confirmation.Thus, morphometry in correlation with cytology, clinical history, physical findings, and radiological data is helpful in guided FNA for a definite diagnosis of SRCT in the region of the kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15754373.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Aydn GB, Kutluk MT, Yalçn B, Büyükpamukçu M, Kale G, Varan A, Akyüz C, Senocak ME, Büyükpamukçu N: Neuroblastoma in Turkish children: experience of a single center. J Pediatr Hematol Oncol; 2009 Jul;31(7):471-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histopathologic subtypes were neuroblastoma (NBL) in 462 patients (92.4%) and ganglioneuroblastoma in 38 patients (7.6%).
  • There were 30, 49, 133, 257, 31 patients with stage 1, 2, 3, 4, 4S disease and their 10-year survival rates were 100%, 75.8%, 34.1%, 6.5%, and 59.4%, respectively.
  • Surgical procedure involving total or near total tumor removal improved the survival (P=0.002).
  • Both 5-year overall survival and event free survival rates were higher when partial resection was performed, especially in stage 3 disease (P=0.002 and P=0.02).
  • In multivariate analysis, age above 18 months at diagnosis (P=0.01), stage 4 disease (P<0.001), abdominal primary tumor site (P<0.001), NBL subtype in histopathology (P=0.001), responsiveness to chemotherapy (P<0.001) positive or high Vanillyl mandelic acid levels (P=0.02) and male sex (P=0.008) were the determinants of poor prognosis.
  • CONCLUSIONS: The survival rates in children with local disease are comparable with the results of developed countries; however, the results in children with advanced disease are still not satisfactory.
  • To improve the outcome, especially in children with advanced disease, more effective chemotherapy regimens and molecular therapies should be investigated.
  • Sharing the knowledge and capacity building to improve the treatment results in NBL are also critical for developing countries.
  • [MeSH-minor] Adolescent. Age Distribution. Age of Onset. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Developing Countries / statistics & numerical data. Female. Humans. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Survival Rate. Turkey

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564739.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hase T, Ohta S, Tani T, Mizukuro T, Mekata E, Naitoh H, Shimadera S, Fujino S, Taga T: Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery? Pediatr Surg Int; 2002 Sep;18(5-6):289-94
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate retrospectively the clinical and biological features that influence the outcome of infants with neuroblastoma (NB) detected by mass screening (NBMS), and to construct surgical strategies to deal with NBMS, 20 infants diagnosed as having either NB or ganglioneuroblastoma (GNB) between 1986 and 1998 were enrolled in a study.
  • The following factors were analyzed by multivariate analysis: age, stage according to the Japanese staging system at the time of diagnosis, site of the primary tumor, histologic findings, preoperative urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) levels, VMA/HVA ratio, lactate dehydrogenase, neuron-specific enolase, Shimada's histologic classification, amplification of the N- myc oncogene by Southern blot analysis, nuclear content, and chromosomal abnormality.
  • Four infants had stage I, 6 stage II, 3 stage III, 3 stage IVB, and 4 stage IV disease.
  • The infant with N- myc-positive NB (stage II) died 23 months after surgery in spite of aggressive postoperative chemotherapy.
  • The N- myc-positive NB case implies that even in locoregional NB detected by NBMS, surgical excision should play a central role in the diagnosis of its oncogenic characteristics and indicate any subsequent therapy.
  • [MeSH-minor] Biomarkers, Tumor / urine. Female. Homovanillic Acid / urine. Humans. Infant. Japan. Male. Mass Screening. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome. Vanilmandelic Acid / urine

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Surg Int. 2002 Sep;18(5-6):288 [12415340.001]
  • (PMID = 12415341.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 55-10-7 / Vanilmandelic Acid; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


26. Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY: [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. Ai Zheng; 2006 Dec;25(12):1550-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
  • BACKGROUND & OBJECTIVE: About 30% of neuroblastoma patients have poor response to first-line chemotherapy or progress during chemotherapy.
  • Although advanced neuroblastoma patients could achieve complete remission after combined treatment, most of them relapsed finally.
  • This study was to evaluate the efficacy of ifosphamide and carboplatin as a salvage chemotherapy regimen on recurrent or refractory neuroblastoma.
  • Mesna was applied at a dosage of 20% of ifosfamide 3 times at 4-hour intervals after termination of the ifosfamide infusion.
  • Chemotherapy was administered every 2-3 weeks.
  • The median remission time was 4.2 months (1-28 months).
  • After chemotherapy, 8 patients received operation to resect tumors.
  • CONCLUSIONS: Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Ifosfamide / administration & dosage. Neuroblastoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Ganglioneuroblastoma / drug therapy. Ganglioneuroblastoma / pathology. Ganglioneuroblastoma / surgery. Humans. Infant. Leukopenia / chemically induced. Male. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Salvage Therapy. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166384.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Sabatino G, Lauriola L, Sioletic S, Puca A: Occipital ganglio-neuroblastoma in an adult. Acta Neurochir (Wien); 2009 May;151(5):495-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occipital ganglio-neuroblastoma in an adult.
  • INTRODUCTION: Ganglioneuroblastomas (GNBs) are embryonic neoplasms, whose behaviour are not well established; 80% of cases occur in the first decade, while only two cases in the adulthood had been reported.
  • CLINICAL REPORT: This 60-year-old female presented with a 2-month history of headache, vertigo, amnesia.
  • A diagnosis of GNB was made from histopathological examination and immunohistochemistry.
  • She underwent fractioned radiotherapy (60 Gy) and chemotherapy with Temozolomide.
  • She remained disease free 18 months after diagnosis.
  • DISCUSSION: Recent observations suggest that in spite of an embryonal appearance, these tumours are circumscribed and have a better prognosis than malignant gliomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ganglioneuroblastoma / diagnosis. Neoplasms, Second Primary / diagnosis. Occipital Lobe / radiography

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262982.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


28. Lara-Bohórquez C, González-Cámpora R, Mendoza-García E, Ríos-Martín JJ, Pareja-Megía MJ, López-Beltrán A: TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors. Anal Quant Cytol Histol; 2008 Apr;30(2):105-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53, BCL-2, p21Waf1/Cip1 and metallothionein as markers of differentiation, response to treatment and prognosis in neuroblastic tumors.
  • OBJECTIVE: To identify markers of response to therapy in neuroblastic tumors.
  • STUDY DESIGN: A total of 58 patients with neuroblastic tumor (38 neuroblastomas, 13 ganglioneuroblastomas and 7 ganglioneuromas) were included in the study.
  • TP53, BCL-2, p21Waf1/Cip1 and metallothionein were included as a biologic approach to tumor differentiation, response to therapy and prognosis.
  • RESULTS: Patients who died of disease had the following immunophenotype: BCL-2 (9 of 10), nuclear TP53 (7 of 10) and metallothionein (7 of 10).
  • TP-53 expression was related to clinical stage (p = 0.062) and disease outcome (p = 0.0218).
  • All patients in whom treatment failed expressed metallothionein (3 of 3).
  • CONCLUSION: TP53, BCL-2, p21Waf1/Cip1 and metallothionein had limited value reflecting tumor maturation (differentiation) or predicting response to therapy.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561747.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


29. Miyauchi J, Kiyotani C, Shioda Y, Kumagai M, Honna T, Matsuoka K, Masaki H, Aiba M, Hata J, Tsunematsu Y: Unusual chromaffin cell differentiation of a neuroblastoma after chemotherapy and radiotherapy: report of an autopsy case with immunohistochemical evaluations. Am J Surg Pathol; 2004 Apr;28(4):548-53
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual chromaffin cell differentiation of a neuroblastoma after chemotherapy and radiotherapy: report of an autopsy case with immunohistochemical evaluations.
  • Ganglionic neuronal differentiation of childhood neuroblastoma is seen with increasing age, leading to more differentiated tumors called ganglioneuroblastomas or ganglioneuromas.
  • Tumor cells with a chromaffin-cell nature have only been detected using histochemical techniques in neuroblastoma cell lines or focal areas of certain in vivo tumors.
  • We describe a neuroblastoma that exhibited an unusual differentiation toward chromaffin cells in a patient that had been treated with surgery, intensive chemotherapy, and radiotherapy.
  • Although a biopsy specimen of the retroperitoneal primary tumor was extensively necrotic, possibly because of a previous chemotherapy regimen, surgically resected metastatic tumors of bilateral ovaries were viable and diagnosed as poorly differentiated neuroblastomas according to the International Neuroblastoma Pathology Classification system.
  • However, metastatic tumors of bilateral lungs examined at the time of autopsy exhibited histologic features similar to those of a pheochromocytoma/paraganglioma, and immunohistochemical examinations demonstrated that these tumors were composed of extra-adrenal chromaffin cells.
  • [MeSH-minor] Cell Differentiation. Child, Preschool. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15087676.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD: Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg; 2006 Aug;41(8):1431-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
  • PURPOSE: Novel treatment strategies for high-risk and disseminated neuroblastoma (NB) are actively sought because of the dismal prognosis of advanced stage disease.
  • TRAIL is capable of inducing apoptosis in multiple tumor cell types, with little or no cytotoxicity against normal cells.
  • The ratio of survivin/TRAIL-R messenger RNA was determined and evaluated as a marker of recurrent disease in patients with NB.
  • Compared with a sensitive cell line (early passage NB16), the resistant cell lines (NB7 and late passage NB16) expressed lesser amounts of the death-inducing TRAIL-R1 and R2, and greater levels of survivin, an inhibitor of apoptosis.
  • Survivin overexpression in a TRAIL-sensitive NB line (early passage NB16) rendered it less sensitive to treatment with TRAIL.
  • A high survivin/TRAIL-R ratio accurately predicted risk for recurrent disease in primary tumor specimens tested.
  • CONCLUSIONS: These findings suggest that TRAIL therapy in combination with specific chemotherapeutic agents may represent an effective therapeutic strategy for NB.
  • The cell's sensitivity to TRAIL is at least partially governed by both TRAIL-R and survivin expression, whereas the ratio between these 2 factors appears to have prognostic value in patients with this disease.
  • [MeSH-major] Apoptosis / drug effects. Apoptosis Regulatory Proteins / pharmacology. Membrane Glycoproteins / pharmacology. Microtubule-Associated Proteins / pharmacology. Neoplasm Proteins / pharmacology. Neuroblastoma / metabolism. Receptors, Tumor Necrosis Factor / biosynthesis. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Child. Etoposide / pharmacology. GPI-Linked Proteins. Ganglioneuroblastoma / metabolism. Ganglioneuroma / metabolism. Humans. Inhibitor of Apoptosis Proteins. Neoplasm Recurrence, Local. Predictive Value of Tests. Receptors, TNF-Related Apoptosis-Inducing Ligand. TNF-Related Apoptosis-Inducing Ligand. Tumor Necrosis Factor Decoy Receptors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863850.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Apoptosis Regulatory Proteins; 0 / BIRC5 protein, human; 0 / GPI-Linked Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFRSF10C protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor Decoy Receptors; 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


31. Mordant P, Le Pimpec-Barthes F, Riquet M: [Neurogenic tumors of the mediastinum in adults]. Rev Pneumol Clin; 2010 Feb;66(1):81-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If the group of neurogenic tumour is frequent, each type of tumour is relatively unusual in everyday's clinic.
  • Treatment of this tumour requires complete preoperative work-up, including standard radiography, CT-scan, MRI, and sometimes nuclear imaging.
  • In most cases, the treatment is based on surgical resection, and may be associated with radiotherapy or chemotherapy in case of malignant tumour or incomplete resection.
  • [MeSH-major] Ganglia, Autonomic. Ganglioneuroblastoma / surgery. Ganglioneuroma / surgery. Mediastinal Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Paraganglioma / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Child. Humans. Prognosis. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20207300.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 64
  •  go-up   go-down


32. Duhem-Tonnelle V, Vinchon M, Defachelles AS, Cotten A, Dhellemmes P: Mature neuroblastic tumors with spinal cord compression: report of five pediatric cases. Childs Nerv Syst; 2006 May;22(5):500-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas neuroblastomas (NB) are relatively common and are generally treated with chemotherapy, mature neuroblastic tumors (MNT), which include intermixed ganglioneuroblastomas (iGNB) and ganglioneuromas (GN), are less common and the role of surgery is more prominent.
  • The neurological and oncological outcomes were generally favorable after surgical resection, followed by orthotic treatment.
  • In one case with neurofibromatosis type 1, the tumor was inoperable and the child died of tumor progression several years later.
  • In case of subtotal removal, tumor remnants can stay stable without oncological treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Nurs Mirror Midwives J. 1975 Nov 6;141(19):48-52 [1042886.001]
  • [Cites] Cancer. 2001 May 15;91(10 ):1905-13 [11346873.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):311-9 [8674009.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):215-20 [1574031.001]
  • [Cites] Pediatr Neurosurg. 2003 Dec;39(6):291-8 [14734862.001]
  • [Cites] J Child Neurol. 1998 Jul;13(7):356-8 [9701489.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):353-9 [10219337.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):579-83 [12948463.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1211-4 [2917322.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1837-40 [4027922.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4 Suppl):875-7 [7611061.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1047-55 [11181668.001]
  • (PMID = 16369850.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK: Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med Pediatr Oncol; 2001 Jan;36(1):194-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
  • Monoclonal antibody 3F8 targeted to GD2 may have imaging and therapeutic potential.
  • PROCEDURE: Among 95 evaluable patients treated intravenously with 3F8 (94 Stage 4, 1 Stage 3), 66 received nonradiolabeled 3F8, 11 received 131-iodine-labeled-3F8 (8-28 mCi/kg) with autologous bone marrow rescue, and 18 received both forms of treatment.
  • Prior to treatment, 90 patients tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 68), tumor immunohistochemistry (n = 20), or diagnostic radioimmunoscintigraphy (n = 2).
  • RESULTS: Of 62 patients who had refractory or recurrent neuroblastoma following 3F8 treatment, 61 (98%) tested positive for GD2 reactivity by bone marrow immunofluorescence (n = 51) or tumor immunohistochemistry (n = 10).
  • CONCLUSIONS: The persistence of GD2 expression in refractory or recurrent NB suggests that complete antigen loss is an uncommon event and cannot account for treatment failure.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Gangliosides / analysis. Immunization, Passive. Immunoconjugates / therapeutic use. Immunoglobulin G / therapeutic use. Iodine Radioisotopes / therapeutic use. Neuroblastoma / therapy. Radioimmunotherapy
  • [MeSH-minor] Antibody Specificity. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Cell Lineage. Child, Preschool. Combined Modality Therapy. Fatal Outcome. Female. Ganglioneuroblastoma / drug therapy. Ganglioneuroblastoma / immunology. Ganglioneuroblastoma / radionuclide imaging. Ganglioneuroblastoma / radiotherapy. Ganglioneuroblastoma / therapy. Humans. Male. Neoplasm Metastasis. Radioimmunodetection. Remission Induction. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464881.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / FDA HHS / FD / FDR001041
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3F8 antibody; 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Gangliosides; 0 / Immunoconjugates; 0 / Immunoglobulin G; 0 / Iodine Radioisotopes; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


34. Yoneda A, Oue T, Imura K, Inoue M, Yagi K, Kawa K, Nishikawa M, Morimoto S, Nakayama M: Observation of untreated patients with neuroblastoma detected by mass screening: a "wait and see" pilot study. Med Pediatr Oncol; 2001 Jan;36(1):160-2
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: Eighteen patients were detected by mass screening between June 1994 and December 1996.
  • Although the remaining three tumors were resected 6-10 months after diagnosis, all patients survived without evidence of recurrence.
  • [MeSH-minor] Biomarkers, Tumor. Chemotherapy, Adjuvant. Disease Progression. Follow-Up Studies. Ganglioneuroblastoma / drug therapy. Ganglioneuroblastoma / epidemiology. Ganglioneuroblastoma / pathology. Ganglioneuroblastoma / surgery. Ganglioneuroblastoma / urine. Genes, myc. Homovanillic Acid / urine. Humans. Infant. Japan / epidemiology. Neoplasm Proteins / blood. Phosphopyruvate Hydratase / blood. Pilot Projects. Prognosis. Prospective Studies. Registries. Treatment Outcome. Vanilmandelic Acid / urine

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464874.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 55-10-7 / Vanilmandelic Acid; EC 4.2.1.11 / Phosphopyruvate Hydratase; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down






Advertisement